Skip to content

Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65

Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02714816
Enrollment
37
Registered
2016-03-22
Start date
2016-04-30
Completion date
2023-07-22
Last updated
2023-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leber Congenital Amaurosis

Brief summary

MGT005 is a natural history study to collect longitudinal prospective data from patients with Leber Congenital Amaurosis associated with defects in RPE65.

Detailed description

Leber Congenital Amaurosis (LCA) is a diagnosis for a group of severe, autosomal recessively inherited rod - cone dystrophies that typically result in complete visual loss in the third or fourth decade of life. One form, LCA2, is caused by a mutation in the gene encoding RPE56, an RPE-specific 65-kDa isomerase. Non-functional RPE65 results in photoreceptor cells that are unable to respond to light resulting in these patients being visually impaired. In preparation for human clinical trials, a detailed prospective phenotypic study will be undertaken to investigate the natural history of RPE65-LCA. Such a study will help identify suitable patients for therapeutic intervention. Furthermore through greater phenotyping an optimal window for intervention and specific parameters to help quantify effect and identify clinical end points may have been ascertained .

Interventions

None listed

Sponsors

MeiraGTx UK II Ltd
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with RPE65 associated retinal dystrophy * Minimum subject age of 3 years * Able to give consent/parent or guardian able to give consent

Exclusion criteria

* Patients unable or unwilling to undertake consent or clinical testing * Have received a gene therapy treatment in both eyes

Design outcomes

Primary

MeasureTime frameDescription
Analysis of retinal structure and function6 yearsRetinal structure will be analysed using Adaptive optics and SD-OCT and Fundal autofluorescence. This will be correlated with assessment of visual acuity, psychophysical visual assessment, visual mobility, retinal sensitivity and visual fields

Secondary

MeasureTime frameDescription
Quality of Life Questionnaires6 yearsAssessment of Visual impairment using appropriate, validated questionnaires
Retinal Sensitivity6 yearsTo be assessed in Microperimetry
Retinal Structural analysis6 yearsRetinal Structure analysis with Adaptive Optics
Fundal Autofluorescence6 yearsPresence or Absence
Assessment of Visual Fields6 yearsAssessment of Visual Fields with analysis of hill of vision

Countries

United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026